243 related articles for article (PubMed ID: 29534357)
21. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
Khurram N; Anis T; Yusuf NW
J Coll Physicians Surg Pak; 2019 Jan; 29(1):33-36. PubMed ID: 30630566
[TBL] [Abstract][Full Text] [Related]
23. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of Metastatic Carcinoma Using Body Cavity Fluid Specimens: A Comparison of Diagnostic Panels.
Sridakhun N; Intarawichian P; Thanee M; Watcharadetwittaya S
Acta Cytol; 2023; 67(3):257-264. PubMed ID: 36513033
[TBL] [Abstract][Full Text] [Related]
25. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
[TBL] [Abstract][Full Text] [Related]
26. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
27. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
28. Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
Kachali C; Eltoum I; Horton D; Chhieng DC
Semin Diagn Pathol; 2006 Feb; 23(1):20-4. PubMed ID: 17044192
[TBL] [Abstract][Full Text] [Related]
29. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Kushitani K; Kai Y; Suzuki R; Miyata Y; Okada M; Takeshima Y
Mod Pathol; 2018 May; 31(5):809-815. PubMed ID: 29327712
[TBL] [Abstract][Full Text] [Related]
30. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
31. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
Nagel H; Hemmerlein B; Ruschenburg I; Hüppe K; Droese M
Pathol Res Pract; 1998; 194(11):759-64. PubMed ID: 9842634
[TBL] [Abstract][Full Text] [Related]
32. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
King JE; Thatcher N; Pickering CA; Hasleton PS
Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
[TBL] [Abstract][Full Text] [Related]
34. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
35. Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.
Cedrés S; Montero MA; Zamora E; Martínez A; Martínez P; Fariñas L; Navarro A; Torrejon D; Gabaldon A; Ramon Y Cajal S; Felip E
Clin Transl Oncol; 2014 Sep; 16(9):776-82. PubMed ID: 24323466
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
[TBL] [Abstract][Full Text] [Related]
37. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
38. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
39. Utility of cell block to detect malignancy in fluid cytology: Adjunct or necessity?
Dey S; Nag D; Nandi A; Bandyopadhyay R
J Cancer Res Ther; 2017; 13(3):425-429. PubMed ID: 28862203
[TBL] [Abstract][Full Text] [Related]
40. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
Marsan C; Gaulier A; Sabatier P; Garcia R
Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
